GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises ...

We recently compiled a list of the 7 Best Medical Technology Stocks To Buy According To Analysts. In this article, we are ...

Local medical device companies last month posted fourth quarter results that exceeded analysts’ expectations.Irvine’s Masimo ...

Glaukos reported robust fourth-quarter revenues, but shares plunged 24.8% post-earnings. Can expanding iDose TR adoption and ...

Glaukos Corporation GKOS reported fourth-quarter 2024 adjusted loss of 40 cents per share, narrower than the Zacks Consensus ...

During the fourth quarter, GKOS’ glaucoma franchise witnessed revenue growth, driven by its iStent portfolio, coupled with growing contributions from iDose TR. Establishing permanent J-code ...

The firm notes Glaukos reported Q4 sales above consensus, driven by iDose and OUS MIGS, offsetting weaker core U.S. MIGS due to LCD headwinds. 2025 sales guidance brackets the Street, with iDose ...

As we pass the 1-year anniversary of our controlled launch of iDose TR, I could not be more pleased with our team's execution of our plans for this first-of-its-kind intracameral procedural ...

In other recent news, Glaukos Corporation has reported promising developments regarding its iDose TR product, with clinical trials demonstrating sustained efficacy in reducing intraocular pressure ...

The firm says its “bullish” key opinion leader checks indicated the “disruptive potential” of iDose across the U.S. glaucoma treatment landscape over the next several years. The checks ...